Literature DB >> 17229223

Does Barrett's oesophagus develop over time in patients with chronic gastro-oesophageal reflux disease?

J Stoltey1, H Reeba, N Ullah, P Sabhaie, L Gerson.   

Abstract

BACKGROUND: Barrett's oesophagus is present in 8-10% of patients with gastro-oesophageal reflux disease (GERD). AIM: We performed a cohort study to determine the incidence of Barrett's oesophagus in patients with chronic heartburn symptoms.
METHODS: We identified patients, with GERD and/or Barrett's oesophagus between 1998 and 2004 by primary or secondary International Classification of Diseases (ICD-9) codes of 530.81 and/or 530.2, who had two or more oesophagogastroduodenoscopies performed at least 6 months apart.
RESULTS: We screened 11 040 patients (41 390 random data entries by ICD-9 code) and enrolled 515 (4.6%) GERD patients and 169 (1.5%) Barrett's oesophagus patients. The mean (+/-s.d.) number of oesophagogastroduodenoscopies in the GERD cohort was 3.2 +/- 1.8 (range: 2-15) over 3.4 +/- 2.2 (range: 0.5-11) years. None of the 412 (80%) GERD patients with non-erosive disease developed Barrett's oesophagus over a mean follow-up time of 3.4 +/- 2.2 years (95% CI: 0-0.9%). Five (1%) of the 103 GERD patients with erosive oesophagitis developed subsequent Barrett's oesophagus. Fifty-seven per cent of the GERD patients were on PPI therapy at the time of index endoscopy. None of the 169 Barrett's oesophagus patients had normal index oesophagogastroduodenoscopies within a mean retrospective time period of 4.5 +/- 2.8 years (95% CI: 0-2%). Using the ICD-9 code of 530.2 as a predictor of the presence of Barrett's oesophagus, the sensitivity was 79% with a specificity of 88%.
CONCLUSION: The majority of patients with GERD do not appear to develop Barrett's oesophagus when it is not present on the index endoscopy.

Entities:  

Mesh:

Year:  2007        PMID: 17229223     DOI: 10.1111/j.1365-2036.2006.03138.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

1.  Gastroesophageal Reflux Frequency, Severity, Age of Onset, Family History and Acid Suppressive Therapy Predict Barrett Esophagus in a Large Population.

Authors:  Omar Bakr; Wei Zhao; Douglas Corley
Journal:  J Clin Gastroenterol       Date:  2018 Nov/Dec       Impact factor: 3.062

2.  Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD.

Authors:  Gerald Holtmann; Marc-André Bigard; Peter Malfertheiner; Roy Pounder
Journal:  Int J Clin Pharm       Date:  2011-04-07

3.  Validation of ICD-9 Code 787.2 for identification of individuals with dysphagia from administrative databases.

Authors:  Marlís González-Fernández; Michael Gardyn; Shamolie Wyckoff; Paul K S Ky; Jeffrey B Palmer
Journal:  Dysphagia       Date:  2009-04-28       Impact factor: 3.438

4.  Risk of upper gastrointestinal cancers in patients with gastroesophageal reflux disease after a negative screening endoscopy.

Authors:  Mohammad H Shakhatreh; Zhigang Duan; Nathaniel Avila; Aanand D Naik; Jennifer R Kramer; Marilyn Hinojosa-Lindsey; John Chen; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2014-07-05       Impact factor: 11.382

5.  Gastroesophageal reflux disease and tooth erosion.

Authors:  Sarbin Ranjitkar; John A Kaidonis; Roger J Smales
Journal:  Int J Dent       Date:  2011-12-12

6.  MicroRNA Expression can be a Promising Strategy for the Detection of Barrett's Esophagus: A Pilot Study.

Authors:  Ajay Bansal; Xiaoman Hong; In-Hee Lee; Kausilia K Krishnadath; Sharad C Mathur; Sumedha Gunewardena; Amit Rastogi; Prateek Sharma; Lane K Christenson
Journal:  Clin Transl Gastroenterol       Date:  2014-12-11       Impact factor: 4.488

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.